Free Trial
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$1.04
-3.7%		$2.12
$1.03
▼
$36.00
$7.37M0.7663,796 shs13,503 shs
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.76
-4.9%		$2.57
$1.75
▼
$12.30
$1.88M1.16932,144 shs26,997 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$4.90
-5.4%		$5.45
$1.90
▼
$10.54
$7.57M3.13,718 shs13,303 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shs1,011 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
-3.70%-18.11%-47.47%-71.72%-93.38%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-4.86%-7.37%-21.43%-48.24%-83.33%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-3.47%-7.81%-6.15%-2.80%-48.54%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%-89.90%-89.90%-79.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$1.04
-3.7%		$2.12
$1.03
▼
$36.00
$7.37M0.7663,796 shs13,503 shs
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.76
-4.9%		$2.57
$1.75
▼
$12.30
$1.88M1.16932,144 shs26,997 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$4.90
-5.4%		$5.45
$1.90
▼
$10.54
$7.57M3.13,718 shs13,303 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shs1,011 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
-3.70%-18.11%-47.47%-71.72%-93.38%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-4.86%-7.37%-21.43%-48.24%-83.33%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-3.47%-7.81%-6.15%-2.80%-48.54%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%-89.90%-89.90%-79.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CalciMedica Inc. stock logo
CALC
CalciMedica
2.20
Hold$50.004,707.69% Upside
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.67
Moderate Buy$44.002,400.00% Upside
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.00
SellN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CANF, CALC, OBSV, and CNSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
9/29/2026
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
8/27/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/20/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy
8/13/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
7/29/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral
7/17/2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/A($2.30) per shareN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$405K4.65N/AN/A$1.76 per share1.00
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$7.29 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CalciMedica Inc. stock logo
CALC
CalciMedica
-$29.56M-$6.80N/AN/AN/AN/AN/A-155.24%11/11/2026 (Estimated)
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$14.80N/AN/AN/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$15.85M-$23.59N/AN/AN/AN/A-204.25%-141.87%11/18/2026 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest CANF, CALC, OBSV, and CNSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2026N/A
CalciMedica Inc. stock logo
CALC
CalciMedica
-$1.2750N/AN/AN/AN/AN/A
8/12/2026Q2 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$0.24-$0.38-$0.14-$0.38N/AN/A
8/11/2026Q2 2026
CalciMedica Inc. stock logo
CALC
CalciMedica
-$1.4250-$0.45+$0.9750-$2.25N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/AN/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CalciMedica Inc. stock logo
CALC
CalciMedica
1.67
5.58
5.58
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
5.86
5.86
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
N/A
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
21.00%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
28.25%
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.80%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.82%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CalciMedica Inc. stock logo
CALC
CalciMedica
156.83 million4.90 millionNo Data
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
51.07 millionN/ANot Optionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
81.46 million1.43 millionNot Optionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
August 31, 2024  |  pharmaphorum.comP
ObsEva SA OBSN
November 11, 2023  |  morningstar.comM
ObsEva SA OBSEF
November 11, 2023  |  morningstar.comM
ObsEva (NASDAQ: OBSV)
June 18, 2023  |  fool.comhttps://www.fool.com/quote/nasdaq/obsv/
Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver
May 10, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance
May 2, 2023  |  news.google.comN
ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq
May 2, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire
May 2, 2023  |  news.google.comN
Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Marketscreener.com
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Yahoo Finance
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Benzinga
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - EIN News
April 28, 2023  |  news.google.comN
Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire
April 28, 2023  |  news.google.comN
Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal
April 26, 2023  |  news.google.comN
Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR
April 23, 2023  |  news.google.comN
ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com
April 21, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - Yahoo Finance
April 20, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - GlobeNewswire
April 20, 2023  |  news.google.comN
Tackling Reproductive Health and Fertility Care - Pharmaceutical Executive
April 13, 2023  |  news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

CalciMedica stock logo

CalciMedica NASDAQ:CALC

$1.04 -0.04 (-3.70%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$1.04 +0.00 (+0.29%)
As of 10/16/2026 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$1.76 -0.09 (-4.86%)
Closing price 10/16/2026 03:59 PM Eastern
Extended Trading
$1.81 +0.05 (+2.95%)
As of 10/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$4.90 -0.28 (-5.42%)
Closing price 10/16/2026 03:10 PM Eastern
Extended Trading
$4.90 +0.00 (+0.02%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas